PRIMAEGISresearch
← Scenarios
MEDPLUS

Medplus Health Services Limited

Drugstore Chains/ NSE
Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target
MEDPLUS
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹705 today
BEAR
₹878
+24%
-1.8% a year · 48.8x exit
BASE
₹1,802
+156%
-1.3% a year · 99.8x exit
BULL
₹2,488
+253%
-0.8% a year · 137x exit
FY27TODAY₹705 today₹2,488₹878₹1,802
Where the market has priced it
45x38x today — outside the range156x
  • the guided figure reached earnings through a low-confidence bridge
  • FY27 one quarter filed — the pace is shown, not judged: guided +0.3%, filed +21.8% across 1 quarter(s)
  • the last 3 years priced this company 40% below its ten-year median (60x vs 100x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
  • at 39x its FY26 earnings the stock trades below the bottom of its own ten-year range (49x)
  • the range is unusually wide — read it as the span of management's own claim, not as a forecast
How these numbers are produced
Earnings baseFY26 fiscal year EPS ₹18.3 (screener)
Guided growth-1.3% a year, said on the call of 24-Jul-2026 · transcript
Read across asoperating: unlabelled growth figure, read as revenue — low confidence
Delivery calibration0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple48.84x / 99.78x / 137x, this company’s own p20 / median / p80 across 5 filed years
Arithmeticbase EPS × (1 + guided growth × delivery)1 × exit multiple
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

What management said

from NSE earnings-call filings · extracted, not interpreted
generic growth 0.3%
And subsequent quarters, we should continuously be around 0.25% to 0.3% growth on overall private label, whereby we believe we will be able to recover the entire decline, what we have.
Call 24-Jul-2026 · bridge confidence low · transcript PDF

Pace against its own guidance

FY27 one quarter filed — the pace is shown, not judged
guided 0.3% filed 21.8% 1 of 4 quarters